Annals of Oncology Advance Access originally published online on September 4, 2007
Annals of Oncology 2007 18(12):2009-2014; doi:10.1093/annonc/mdm374
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2007 European Society for Medical Oncology
lung cancer |
Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer
1 Department of Internal Medicine, Seoul National University Hospital, Seoul
2 Cancer Research Institute, Seoul National University College of Medicine, Seoul
3 Department of Internal Medicine, Kyung Hee University Hospital, Seoul
4 Department of Internal Medicine, St Vincent's Hospital, Suwon
5 Department of Internal Medicine, Asan Medical Center, Seoul
6 Department of Internal Medicine, Korea University Anam Hospital, Seoul
7 Department of Internal Medicine, Korea University Guro Hospital, Seoul
8 Department of Medicine, Samsung Medical Center, Seoul
9 Samyang Corporation, Seoul, Korea
* Correspondence to: Prof. D. S. Heo, Department of Internal Medicine, Seoul National University Hospital, 28 Yongon-Dong, Chongro-Gu, Seoul 110-744, Korea. Tel: +82-2-2072-2857; Fax: +82-2-747-2199; E-mail: heo1013{at}plaza.snu.ac.kr
Background: Genexol-PM is a novel Cremophor EL (CrEL)-free polymeric micelle formulation of paclitaxel (Taxol). This multicenter phase II study was designed to evaluate the efficacy and safety of the combination of Genexol-PM and cisplatin for the treatment of advanced non-small-cell lung cancer (NSCLC).
Patients and methods: Patients with advanced NSCLC received Genexol-PM 230 mg/m2 and cisplatin 60 mg/m2 on day 1 of a 3-week cycle as first-line therapy. Intrapatient dose escalation of Genexol-PM to 300 mg/m2 was carried out from the second cycle if the prespecified toxic effects were not observed after the first cycle.
Results: Sixty-nine patients were enrolled in this study. Overall response rate was 37.7%. The median time to progression was 5.8 months and the median survival period was 21.7 months. The major non-hematologic toxic effects included grade 3 peripheral sensory neuropathy (13.0%) and grade 3/4 arthralgia (7.3%). Four patients (5.8%) experienced grade 3/4 hypersensitivity reactions. The major hematological toxic effects were grade 3/4 neutropenia (29.0% and 17.4%, respectively).
Conclusion: Genexol-PM plus cisplatin combination chemotherapy showed significant antitumor activity. The use of CrEL-free, polymeric micelle formulation of paclitaxel allowed administration of higher doses of paclitaxel compared with the CrEL-based formulation without significant increased toxicity.
Key words: chemotherapy, Genexol-PM, non-small-cell lung cancer, phase II
Received for publication January 12, 2007. Revision received June 22, 2007. Accepted for publication July 2, 2007.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  W. T. Lim, E. H. Tan, C. K. Toh, S. W. Hee, S. S. Leong, P. C. S. Ang, N. S. Wong, and B. Chowbay Phase I pharmacokinetic study of a weekly liposomal paclitaxel formulation (Genexol(R)-PM) in patients with solid tumors Ann. Onc., July 24, 2009; (2009) mdp315v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Patel, T. A. Hensing, A. Rademaker, E. M. Hart, M. G. Blum, D. T. Milton, and P. D. Bonomi Phase II Study of Pemetrexed and Carboplatin Plus Bevacizumab With Maintenance Pemetrexed and Bevacizumab As First-Line Therapy for Nonsquamous Non-Small-Cell Lung Cancer J. Clin. Oncol., July 10, 2009; 27(20): 3284 - 3289. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Bisht, G. Feldmann, J.-B. M. Koorstra, M. Mullendore, H. Alvarez, C. Karikari, M. A. Rudek, C. K. Lee, A. Maitra, and A. Maitra In vivo characterization of a polymeric nanoparticle platform with potential oral drug delivery capabilities Mol. Cancer Ther., December 1, 2008; 7(12): 3878 - 3888. [Abstract] [Full Text] [PDF]
|
|